Physician profile
Mary E Dailey
NPI 1720012776
$1,865.02
in general payments reported to CMS, 2019-2025
15 companies · $419 in 2025
The $419 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $306 · 2022: $228 · 2023: $375 · 2024: $537 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,331.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $909.77 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $371.27 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $142.90 | 2022-2025 | Rybelsus, Ozempic |
| Phathom Pharmaceuticals, INC. | $102.88 | 2024 | Voquezna |
| Teleflex LLC | $65.09 | 2023-2025 | Urolift, Barrigel |
| Amgen INC. | $53.15 | 2021 | |
| Lilly USA, LLC | $49.12 | 2022-2024 | Mounjaro |
| Axonics, INC. | $39.85 | 2023-2024 | Axonics |
| Tolmar, INC. | $33.44 | 2024-2025 | Jatenzo, Eligard |
| Dendreon Pharmaceuticals LLC | $24.09 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.01 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $16.05 | 2023 | Gvoke Hypopen |
| Organon LLC | $13.78 | 2022 | |
| Dexcom, INC. | $12.74 | 2022 | |
| Genentech USA, INC. | $8.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Dailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.